MNG979
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.567
- G2M_CHECKPOINT+0.521
- UNFOLDED_PROTEIN_RESPONSE+0.453
- MYC_TARGETS_V1+0.442
- MITOTIC_SPINDLE+0.418
- MTORC1_SIGNALING+0.367
- MYC_TARGETS_V2+0.338
- DNA_REPAIR+0.323
- INTERFERON_ALPHA_RESPONSE+0.273
- PROTEIN_SECRETION+0.241
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.316
- IL2_STAT5_SIGNALING-0.275
- COAGULATION-0.260
- APICAL_SURFACE-0.223
- BILE_ACID_METABOLISM-0.223
- TNFA_SIGNALING_VIA_NFKB-0.218
- KRAS_SIGNALING_UP-0.211
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.207
- INFLAMMATORY_RESPONSE-0.190
- HEME_METABOLISM-0.186
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG387 | — | — | 0.847 |
| 2 | TCGA-77-7138-01A-41R-2045-07 | — | cohortSQ1 | 0.842 |
| 3 | TCGA-91-6836-01A-21R-1858-07 | — | cohortA1 | 0.842 |
| 4 | BS_P7EY9DXG | ATRT | — | 0.833 |
| 5 | SRR12475103 | — | — | 0.830 |
| 6 | SRR15030853 | — | — | 0.830 |
| 7 | 1c7309b2-91f0-4305-aad7-f86c0d143559 | — | — | 0.830 |
| 8 | TCGA-CR-6493-01A-11R-1873-07 | — | — | 0.828 |
| 9 | TCGA-E2-A109-01A-11R-A10J-07 | — | B | 0.824 |
| 10 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.567 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.521 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.453 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.442 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.418 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.367 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.338 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.323 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.273 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.241 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.176 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.166 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.104 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.095 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.091 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.056 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.023 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.009 | Inavolisib | — uncovered |